Oramed Pharmaceuticals Inc.
ORMP
Rank in Stocks
#17485
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York,... Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Share Price
$4.00
Last synced: 2026-11-09
Market Cap
$166.39M
Change (1 day)
3.63%
Change (1 year)
65.29%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oramed Pharmaceuticals Inc. (ORMP)
Category
Healthcare
Operating Margin for Oramed Pharmaceuticals Inc. (ORMP)
Operating Margin as of November 2026 TTM: 0.00%
According to Oramed Pharmaceuticals Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -754.40%.
Operating Margin history for Oramed Pharmaceuticals Inc. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -754.40% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -1,176.79% | -21.65% |
| 2022 | -1,501.96% | 67.60% |
| 2021 | -896.15% | 106.56% |
| 2020 | -433.84% | -19.85% |
| 2019 | -541.29% | -2.00% |
| 2018 | -552.35% | 25.95% |
| 2017 | -438.56% | -71.92% |
| 2016 | -1,561.62% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | 1,565.24% | -226.88% |
| 2011 | -1,233.60% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oramed Pharmaceuticals Inc.'s operating margin
What was Oramed Pharmaceuticals Inc.'s operating margin in 2025?
In 2025, Oramed Pharmaceuticals Inc.'s operating margin was -754.40%, compared with 0.00% in 2024.
How has Oramed Pharmaceuticals Inc.'s operating margin changed since 2020?
From 2020 to 2025, Oramed Pharmaceuticals Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2022 (-1,501.96%).
How does Oramed Pharmaceuticals Inc.'s operating margin compare with similar companies?
Oramed Pharmaceuticals Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.